Market Research Logo

Newron Pharmaceuticals SpA (NWRN) - Financial and Strategic SWOT Analysis Review

Newron Pharmaceuticals SpA (NWRN) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Newron Pharmaceuticals SpA (Newron) is a research-based biopharmaceutical company which focuses on the discovery, development and commercialization of novel therapeutic drugs for the treatment of central nervous system disorders and pain. The company’s marketed product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson's disease. Newron’s other products in pipeline include ralfinamide for neuropathic pain; sarizotan for Rett syndrome; and Evenamide (NW-3509) for the treatment of schizophrenia. The company has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co., Ltd. It operates along with its subsidiaries in the UK, Sweden, Switzerland and the US. Newron is headquartered in Bresso, Milan, Italy.

Newron Pharmaceuticals SpA Key Recent Developments

Mar 27,2018: Newron Pharmaceuticals Announces Shareholders Accepted All Motions at the AGM 2018
Mar 01,2018: Newron Announces 2017 Financial Results and Provides Outlook for 2018
Feb 13,2018: Newron Supports Global Rare Disease Day 2018 and Rett Syndrome Studies
Dec 11,2017: Newron Provides End of Year Corporate Update
Nov 07,2017: Newron Pharmaceuticals Announces Advisory Board Recommendations and Rett Congress Findings

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Newron Pharmaceuticals SpA - Key Facts
Newron Pharmaceuticals SpA - Key Employees
Newron Pharmaceuticals SpA - Key Employee Biographies
Newron Pharmaceuticals SpA - Major Products and Services
Newron Pharmaceuticals SpA - History
Newron Pharmaceuticals SpA - Company Statement
Newron Pharmaceuticals SpA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Newron Pharmaceuticals SpA - Business Description
Newron Pharmaceuticals SpA - Corporate Strategy
Newron Pharmaceuticals SpA - SWOT Analysis
SWOT Analysis - Overview
Newron Pharmaceuticals SpA - Strengths
Newron Pharmaceuticals SpA - Weaknesses
Newron Pharmaceuticals SpA - Opportunities
Newron Pharmaceuticals SpA - Threats
Newron Pharmaceuticals SpA - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Newron Pharmaceuticals SpA, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 27, 2018: Newron Pharmaceuticals Announces Shareholders Accepted All Motions at the AGM 2018
Mar 01, 2018: Newron Announces 2017 Financial Results and Provides Outlook for 2018
Feb 13, 2018: Newron Supports Global Rare Disease Day 2018 and Rett Syndrome Studies
Dec 11, 2017: Newron Provides End of Year Corporate Update
Nov 07, 2017: Newron Pharmaceuticals Announces Advisory Board Recommendations and Rett Congress Findings
Sep 14, 2017: Newron reports half-year 2017 results
May 18, 2017: Newron Announces a Poster Presentation at the International Society for Pharmacoeconomics and Outcomes Research 22nd Annual International Meeting
Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia
Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinson’s disease in Japan and Asia
Mar 02, 2017: Newron announces 2016 financial results and provides outlook for 2017
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Newron Pharmaceuticals SpA, Key Facts
Newron Pharmaceuticals SpA, Key Employees
Newron Pharmaceuticals SpA, Key Employee Biographies
Newron Pharmaceuticals SpA, Major Products and Services
Newron Pharmaceuticals SpA, History
Newron Pharmaceuticals SpA, Subsidiaries
Newron Pharmaceuticals SpA, Key Competitors
Newron Pharmaceuticals SpA, Ratios based on current share price
Newron Pharmaceuticals SpA, Annual Ratios
Newron Pharmaceuticals SpA, Annual Ratios (Cont...1)
Newron Pharmaceuticals SpA, Interim Ratios
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Newron Pharmaceuticals SpA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Newron Pharmaceuticals SpA, Performance Chart (2013 - 2017)
Newron Pharmaceuticals SpA, Ratio Charts
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report